Neuroptis Biotech reports positive results from ML7 preclinical trials for eye surface diseases

Neuroptis Biotech, the ophthalmology drug research and development specialist, announces positive results in preclinical trials of the eye-drop formulation of its ML7 product. ML7 is intended for use in the treatment of eye surface diseases, particularly dry eye.

Full Story →